Hikma Pharmaceuticals (OTCMKTS:HKMPF) Reaches New 1-Year Low - What's Next?

Key Points

• Hikma hit a new 52-week low of $16.3425 on Friday, down about 9.2% from the prior close of $18.00 on light volume (225 shares).
• Barclays downgraded the stock from "hold" to "strong sell" on Jan. 6, while overall coverage remains mixed (one Buy, one Sell) leaving an average rating of "Hold".
• The shares are trading well below key technical levels (50‑day $20.74, 200‑day $21.84); the company reports modest leverage (debt/equity 0.33) but limited short-term liquidity (current ratio 1.24, quick ratio 0.72).

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Friday . The company traded as low as $16.3425 and last traded at $16.3425, with a volume of 225 shares traded. The stock had previously closed at $18.00.

Analyst Upgrades and Downgrades

Separately, Barclays lowered shares of Hikma Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Tuesday, January 6th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Hikma Pharmaceuticals presently has an average rating of "Hold".

Hikma Pharmaceuticals Stock Down 9.2%

The firm has a fifty day moving average of $20.74 and a 200 day moving average of $21.84. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.24 and a quick ratio of 0.72.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company's three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.